Rapid COVID‐19 antigenic tests: Usefulness of a modified method for diagnosis
Open Access
- 19 May 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5655-5659
Abstract
The current reliable recommended test for coronavirus disease 2019 (COVID‐19) diagnosis is quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR). Rapid antigen test devices could be useful as they are less expensive, faster without the need of specialized laboratories to perform the test. We report the performances of two rapid immunochromatographic antigen testing devices compared with RT‐qPCR for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal samples. We carried out a lateral‐flow tests study on 401 nasopharyngeal swab samples from nonduplicated suspected COVID‐19 subjects. An equal volume of universal transport medium tubes‐containing samples (dilution ratio = 1:15) were added to the manufacturer's extraction buffer solution (dilution ratio = 1:2) and analyzed on BioSpeedia COVID19Speed‐Antigen Test and on Abbott Panbio™ COVID‐19 Ag Rapid Test, devices. Qualitative results were compared to those obtained by the RT‐qPCR (Allplex™ SARS‐CoV‐2 Assay Seegene). Based on our data, the overall sensitivity for BioSpeedia and Panbio devices was estimated at 65.5% and 75.0%, respectively. The sensitivity was greater for cycle threshold values less than 25 achieving 90.4 and 96.8 for BioSpeedia and Panbio devices, respectively. A perfect specificity of 100.0% was observed for both devices.Keywords
This publication has 8 references indexed in Scilit:
- Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 InfectionJournal of Clinical Medicine, 2021
- Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infectioneClinicalMedicine, 2021
- Comparison of Rapid Antigen Tests for COVID-19Viruses, 2020
- Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptomsJournal of Clinical Virology, 2020
- Mass Screening Vs Lockdown Vs Combination of Both to Control Covid-19: A Systematic ReviewJournal of Public Health Research, 2020
- Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID‐19 patientsJournal of Medical Virology, 2020
- Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosisJournal of Clinical Virology, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020